Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to
reduce the burden placed on health systems, the situation remains critical. Effective …

Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics
for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies …

Antibodies binding to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike have therapeutic promise, but emerging variants show the potential for virus escape …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variants have risen to dominance, which contains far more mutations in the spike protein in …

Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) Omicron variant sub-
lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has …

The spike glycoprotein of SARS-CoV-2 engages with human ACE 2 to facilitate infection.
Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that …

The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus,
continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that …

The COVID‐19 pandemic continues to be a severe threat to human health, especially due to
current and emerging SARS‐CoV‐2 variants with potential to escape humoral immunity …

The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in
the face of the global COVID-19 pandemic, as such reagents can have important diagnostic …